AIRNA’s therapy for alpha1 antitrypsin deficiency, or AATD, edits RNA to address the underlying cause of this rare inherited disease. Wave Life Sciences and Korro Bio are both further along in the development of RNA-editing therapies for AATD, but AIRNA claims its therapy could be best in class.
The post Biotech Startup AIRNA Adds $60M to Advance RNA-Editing Therapy for Rare Protein Deficiency appeared first on MedCity News.
Related Articles
When It Comes to AI, Rural Doctors Have FOMO — Meditech & Suki Are Teaming Up to Address This
Meditech is integrating Suki’s AI assistant into more than a dozen rural...
FTC to sue PBMs over insulin pricing and rebates
From the FTC’s press release out today: Today, the Federal Trade Commission...
World Mental Health Day 2024
Every year, World Mental Health Day is an opportunity for mental health...
North Carolina’s Effort to Relieve Medical Debt
This policy watch examines the burden of medical debt in North Carolina...
Leave a comment